Overview
Lobbying Costs
350,000€
Financial year: Jan 2019 - Dec 2019
Lobbyists (Full time equivalent)
1.25 Fte (3)
Lobbyists with EP accreditation
0
High-level Commission meetings
3
Lobbying Costs over the years
-
Info
European Society for Medical Oncology (ESMO) (ESMO)
EU Transparency Register
947929324977-41 First registered on 08 Dec 2016
Goals / Remit
ESMO is the leading professional organisation for medical oncology. We are the society of reference for oncology education and information, and are committed to supporting our members to develop and advance in a fast-evolving professional environment. Cancer patients and their needs are at the centre of all that we do: our profession is driven by our determination, individually and collectively, to secure the best possible outcomes for people with cancer across Europe and around the world.
ESMO's mission is:
-To improve the quality of prevention, diagnosis, treatment, supportive and palliative care, as well as the follow-up of patients with malignant diseases
-To advance the art, science, recognition, and practice of oncology
-To disseminate knowledge to cancer patients and the public
-To ensure a high standard of qualification of medical oncologists within the multidisciplinary team
-To promote equal access to optimal cancer care for all cancer patientsMain EU files targeted
EU policy fields of interest for ESMO include Health, Cancer, Chronic Diseases, Research and Innovation, Cross Border Health Care, Health Technology Assessment, Data Protection, Clinical Trials, Digitalisation, Orphan and Paediatric Medicines, Rare Diseases.
Address
Head Office
Via Ginevra 4
Lugano 6900
SWITZERLANDEU Office
Square de Meeûs 37
4th Floor
Brussels 1000
BELGIUM -
People
Total lobbyists declared
3
Employment time Lobbyists 50% 2 25% 1 Lobbyists (Full time equivalent)
1.25
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
0 accreditations were / are live (in bold) for the selected state of 25 May 2021
Name Start date End Date Agata KUSIAK 17 Feb 2024 14 Feb 2025 Tanya KENNY 07 Mar 2024 06 Mar 2025 Paul James LAFFIN 22 Feb 2024 21 Feb 2025 Marijn SCHOLTE 14 Dec 2023 13 Dec 2024 Robert Delis 10 Apr 2024 10 Apr 2026 Ms Tanya KENNY 07 Mar 2024 15 Apr 2024 Mr Paul James LAFFIN 22 Feb 2024 15 Apr 2024 Ms Agata KUSIAK 17 Feb 2024 15 Apr 2024 Mr Marijn Scholte 14 Dec 2023 15 Apr 2024 Mr Robert Delis 18 Apr 2023 15 Apr 2024 Mr Paul James LAFFIN 19 Oct 2022 19 Oct 2023 Ms Daniela Morghenti 15 Oct 2022 14 Oct 2023 Mr Marijn Scholte 06 Oct 2022 05 Oct 2023 Ms Fiona GREENHALGH 20 Feb 2020 01 Mar 2021 Ms Anna CARTA 07 Nov 2019 07 Nov 2020 Ms Emilie Hoogland 12 Mar 2019 01 Apr 2020 Ms Malvika Vyas 06 Mar 2019 29 Feb 2020 Ms Anna CARTA 22 Sep 2018 01 Oct 2019 Mr Paolo Casali 14 Apr 2018 13 Apr 2019 Ms Malvika Vyas 02 Mar 2018 02 Mar 2019 Ms MONICA GHEORGHE 31 Aug 2017 31 Aug 2018 Ms Malvika Vyas 23 Jan 2017 19 Jan 2018 Ms Aurélie Paviza 23 Jan 2017 31 Aug 2017 Mr Paolo Casali 23 Jan 2017 19 Jan 2018 Complementary Information
None declared
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
II - In-house lobbyists and trade/business/professional associations
Subcategory
Trade unions and professional associations
-
Networking
Affiliation
ESMO is a Founding Member of: Rare Cancers Europe (RCE), Rare Cancers Asia (RCA), European Chronic Disease Alliance (ECDA), European Alliance for Personalized Medicine (EAPM). ESMO is a Full Member of the Union of International Cancer Control (UICC, Geneva), and the European Medicines Agency (EMA) Healthcare Professionals Working Party. ESMO is an Associate Member of the NCD Alliance. ESMO also takes part in the Stakeholder Pool of the European Commission Health Technology Assessment Network. ESMO has 'Official Relations Status' with the World Health Organization (WHO), and 'Special Consultative Status' with the United Nations Economic and Social Council (ECOSOC).
Member organisations
None declared
-
Financial Data
Closed financial year
Jan 2019 - Dec 2019
Lobbying costs for closed financial year
350,000€
Other financial info
https://www.esmo.org/about-esmo/how-we-work/esmo-funding
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
N/A
Communication activities
None
Other activities
None declared
- Meetings
Meetings
3 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
-
Date 26 May 2020 Location Brussels Subject VC meeting to discuss the EU's Cancer Plan and its objectives, cancer care and treatment during the COVID-19 pandemic Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Stella Kyriakides (Commissioner)
Other Lobbyists -
Date 21 Jan 2020 Location Brussels Subject Discussion on cancer Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Stella Kyriakides (Commissioner)
Other Lobbyists -
Date 03 May 2018 Location Brussels Subject HTA Cabinet Cabinet of Commissioner Vytenis Andriukaitis Portfolio Health & Food Safety Attending - Vytenis Andriukaitis (Commissioner)
- Annika Nowak (Cabinet member)
Other Lobbyists - European Union of General Practitioners / Family Physicians (Union Européenne des Médecins Omnipraticiens / Médecins de Famille)
- European Hospital and Healthcare Federation
- European Society of Cardiology
- European Public Health Association
- European Forum for Primary Care
- Standing Committee of European Doctors
- The European Association of Hospital Pharmacists
- Phamaceutical Group of the European Union
- European Organisation for Research and Treatment of Cancer
- Meetings